Pharmaceutical

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

Trial investigators anticipate that the FDA will decide on approval for linvoseltamab in relapsed/refractory multiple myeloma by the end of 2024.

Jun 22, 2024 - 04:00
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments
Trial investigators anticipate that the FDA will decide on approval for linvoseltamab in relapsed/refractory multiple myeloma by the end of 2024.
Read the original article

Tags:

Previous Article

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likeliho...

Next Article

Sarepta’s Elevidys secures US label expansion for DMD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Indena’s CDMO services: Full manufacturing capabilities for pharma ingredients

Indena’s CDMO services: Full manufacturing capabilities...

Mar 13, 2024

Causaly secures $60 Million in series B funding

Causaly secures $60 Million in series B funding

Jul 15, 2023

Novo faces growth challenges despite GLP-1 receptor agonist obesity boom

Novo faces growth challenges despite GLP-1 receptor ago...

Aug 1, 2024